An Open Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for Injection in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 14 Apr 2017
At a glance
- Drugs Docetaxel (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Jina Pharmaceuticals
- 08 Apr 2017 Status changed from active, no longer recruiting to completed.
- 07 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
- 07 Apr 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.